Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.58 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26743907 | 0.93 | NOD1 (0.67) | NOD1GLP1REPHX2 | |
| SCHEMBL29300200 | 0.90 | MMP2 (0.53) | NOD1CASP2GLP1RNAAA | |
| SCHEMBL21389121 | 0.89 | CASP2 (0.53) | NOD1CASP2GLP1RFAAHEPHX2 | |
| SCHEMBL20016978 | 0.88 | CASP2 (0.51) | NOD1CASP2GLP1RFAAHEPHX2 | |
| SCHEMBL21389124 | 0.88 | CASP2 (0.51) | NOD1CASP2FAAHEPHX2NAAA | |
| SCHEMBL24494715 | 0.87 | NOD1 (0.60) | NOD1GLP1RFAAHEPHX2 | |
| SCHEMBL21389120 | 0.87 | NOD1 (0.63) | NOD1GLP1REPHX2 | |
| SCHEMBL21389122 | 0.86 | NOD1 (0.62) | NOD1GLP1REPHX2 | |
| SCHEMBL21389084 | 0.86 | NOD1 (0.62) | NOD1GLP1REPHX2 | |
| SCHEMBL17479992 | 0.86 | NOD1 (0.61) | NOD1CASP2GLP1RFAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | NOD1 1118/4885CASP2 1983/4885GLP1R 2/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | NOD1 1162/4885CASP2 2051/4885GLP1R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.